SHORT MINI-FUTURE - GILEAD SCIENCES | Real-time Bid/Ask 08:52:43 2024-05-24 am EDT | ||
| 3.79 EUR / 3.81 EUR | -0.52% |
|
| Current month | -3.78% | ||
| 1 month | +1.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 3.79 | -0.79% |
| 24-05-23 | 3.82 | +2.96% |
| 24-05-22 | 3.71 | +0.27% |
| 24-05-21 | 3.7 | +1.37% |
| 24-05-20 | 3.65 | -0.82% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 08:40 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VZ6XG5 |
| ISIN | DE000VZ6XG56 |
| Date issued | 2014-10-10 |
| Strike | 107.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.97 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.13 € |
|---|---|
| Lowest since issue | 1.84 € |
| Spread | 0.02 € |
| Spread % | 0.52% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.17
USD
Average target price
82.77
USD
Spread / Average Target
+25.09%
- Stock Market
- Certificates
- Certificat
